AIBIOOS logo AIBIOOS
EN 中文

News

Tireless exploration across AI and life science

This channel curates public updates from regulators, research institutions, and technology companies, with links back to original sources.

Editorial Scope

What we track

AI Life Science NAMs Organoids AI Medical Devices Regulatory Science
FDA

FDA reports first-year progress reducing animal testing in drug development

FDA highlighted progress in advanced in vitro systems, computational modeling, and human-derived platforms, reinforcing the shift toward human-relevant evidence generation.

Read source
FDA

FDA draft guidance addresses validation of alternatives to animal testing

The draft guidance outlines recommendations for validating new approach methodologies when nonclinical alternatives are submitted in drug development.

Read source
NIH Record

NIH establishes organoid development center with AI and robotics

NIH described a standardized organoid center combining AI, robotics, human cell sources, and shared repositories to improve reproducibility.

Read source
FDA

FDA deploys agentic AI capabilities across the agency

FDA announced optional agentic AI tools for employees, signaling broader institutional adoption of AI workflows in scientific and operational contexts.

Read source
NVIDIA Newsroom

BioNeMo adoption highlights AI infrastructure for drug discovery

Growing adoption of AI platforms, agentic workflows, and accelerated computing is reshaping drug discovery infrastructure.

Read source
Google DeepMind

AlphaFold impact underscores the rise of digital biology

DeepMind positioned AlphaFold as part of a broader movement toward digital biology and AI-enabled drug discovery.

Read source

Editorial Note

Curated public information, not a substitute for the original source

Each entry is a short editorial summary linked to the original public source. The channel can keep growing as AIBIOOS expands its thematic coverage.